GlassScriptPhysician profile
Melissa E Raffaele
NPI 1962727081
$1,551.84
in general payments reported to CMS, 2019-2025
28 companies · $20.22 in 2025
The $20.22 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $345 · 2022: $432 · 2023: $247 · 2024: $509 · 2025: $20.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.14 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $269.92 | 2021-2024 | Wegovy |
| Idorsia Pharmaceuticals US INC | $138.70 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $121.55 | 2022-2023 | Olumiant, Taltz |
| Ardelyx, INC. | $103.45 | 2022-2023 | Ibsrela |
| Beta Bionics, INC. | $76.75 | 2024 | Ilet Bionic Pancreas |
| Insulet Corporation | $74.13 | 2024 | Omnipod |
| Medtronic, INC. | $69.86 | 2024 | Minimed 780g |
| Teva Pharmaceuticals USA, INC. | $65.01 | 2024 | Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.65 | 2021-2023 | Jardiance |
| Amgen INC. | $56.47 | 2021-2024 | Repatha |
| Abbvie INC. | $53.12 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $49.21 | 2024 | Ultomiris |
| Pfizer INC. | $49.17 | 2021-2022 | |
| Inari Medical, INC. | $47.33 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Corcept Therapeutics | $41.16 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $37.59 | 2021-2022 | |
| Dexcom, INC. | $33.88 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $33.09 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $20.64 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2025 | |
| Amarin Pharma, INC. | $18.57 | 2021 | |
| Almatica Pharma LLC | $18.49 | 2021 | |
| Daiichi Sankyo INC. | $18.39 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.23 | 2021 | |
| Lundbeck LLC | $15.53 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.16 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Raffaele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.